In a report released yesterday, Sam Slutsky from LifeSci Capital maintained a Buy rating on Enliven Therapeutics, with a price target of $39.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sam Slutsky has given his Buy rating due to a combination of factors tied to Enliven’s lead program and financial strength. He views ELVN-001’s Phase 1b data in chronic myeloid leukemia as highly encouraging, with strong major and deep molecular response rates that appear consistent across the tested dose range, implying the drug is already operating near peak efficacy without clear safety trade-offs.
He also highlights the company’s intention to launch a pivotal Phase 3 trial in the second half of 2026 in the second-line and later CML setting, which he believes could unlock meaningful value if successful. Combined with a cash position of roughly $463 million that is projected to fund operations into the first half of 2029, Slutsky sees Enliven as well capitalized to reach and potentially read out pivotal data, supporting his view that ELVN-001 could emerge as a leading active-site TKI option in CML and justifying a Buy recommendation.